Clinical Trial

Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2024 (before its estimated October 3, 2025 completion). Its status may not reflect the trial's current state.
Summary
After surgery is completed under general anesthesia, extubation is performed after recovery from anesthesia, and during this process, bucking, coughing, and rapid and excessive hemodynamic fluctuations occur very often. These phenomena can lead to high intrathoracic pressure, venous congestion, hematoma formation, or increased bleeding after major neck surgery. (1) They can also increase the risk of aerosol generation, which can transmit infection to health care workers. (2) For this, smooth extubation is required. Methods of administering drugs such as lidocaine, opioids, or dexmedetomidine have been proposed for smooth extubation. (3-5) As a disadvantage, the use of these drugs may be associated with deep sedation and reduced airway reflexes . Recently, Babu et al. (6) reported that bucking and coughing during extubation could be reduced by changing the timing of administering a muscle relaxant antagonist rather than using these sedative drugs, and thus complications related to extubation could be reduced. In general, in the awakening process, it was common to administer the muscle relaxant at the point of recovery of spontaneous breathing. However, Babu et al. demonstrated the possibility of safe and smooth extubation by changing the timing of administering neostigmine without the use of sedatives or narcotic analgesics, but there are few studies on sugammadex. Therefore, when recovering from general anesthesia, sugammadex was administered before and immediately after extubation to evaluate and compare smooth extubation (ie, comparison of the frequency of bucking and coughing).
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05751603
Lead Sponsor Ajou University School of Medicine
Conditions Sugammadex, Extubation, Smooth Emergence
Enrollment 66 participants
Start Date 2024-10-03
Primary Completion 2025-10-03 (estimated)
Study Completion 2025-10-03 (estimated)
Updated on ClinicalTrials.gov 2024-07-25